Overview

Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse

Status:
Recruiting
Trial end date:
2029-12-01
Target enrollment:
Participant gender:
Summary
Daratumumab for first line treatment of transplant-ineligible myeloma patients followed by daratumumab re-treatment at first relapse (GMMG-DADA)
Phase:
Phase 2
Details
Lead Sponsor:
University of Cologne
Collaborator:
Janssen-Cilag G.m.b.H
Treatments:
Daratumumab